Trials / Conditions / Resectable Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

18 registered clinical trials studyying Resectable Hepatocellular Carcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	THIO and Cadonilimab in Resectable Hepatocellular Carcinoma NCT07446257	University of Texas Southwestern Medical Center	EARLY_Phase 1
Not Yet Recruiting	Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatme NCT07018947	Fundacion Clinic per a la Recerca Biomédica	Phase 2
Recruiting	Neoadjuvant Triple Therapy for Resectable HCC NCT06569498	Fujian Provincial Hospital	—
Active Not Recruiting	Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma NCT06524466	Sun Yat-sen University	Phase 2
Completed	Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carc NCT05807776	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	SIRT With Tremelimumab and Durvalumab for Resectable HCC NCT05701488	Jiping Wang, MD, PhD	Phase 1
Unknown	AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) NCT05578430	Sun Yat-sen University	Phase 2
Unknown	Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellul NCT05519410	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Withdrawn	Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer NCT04965714	M.D. Anderson Cancer Center	Phase 2
Recruiting	18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant NCT02379377	M.D. Anderson Cancer Center	Phase 1
Completed	Surgical Resection for Hepatocellular Carcinoma NCT06013657	Dr Cipto Mangunkusumo General Hospital	—
Active Not Recruiting	Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer NCT04856046	Mayo Clinic	—
Active Not Recruiting	SBRT + Atezolizumab + Bevacizumab in Resectable HCC NCT04857684	Massachusetts General Hospital	EARLY_Phase 1
Unknown	Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcino NCT04834986	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Active Not Recruiting	Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer NCT04721132	M.D. Anderson Cancer Center	Phase 2
Completed	Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma NCT04701060	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Completed	Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer NCT03222076	M.D. Anderson Cancer Center	Phase 2
Completed	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820	Roswell Park Cancer Institute	Phase 1